Health & Fitness
Tue, January 17, 2012Mon, January 16, 2012Fri, January 13, 2012Thu, January 12, 2012Wed, January 11, 2012Tue, January 10, 2012Mon, January 9, 2012Sun, January 8, 2012Sat, January 7, 2012Fri, January 6, 2012Thu, January 5, 2012Wed, January 4, 2012Tue, January 3, 2012Aethlon Medical Discloses Availability of the Biotech Showcasea" 2012 Presentation
Published in Health and Fitness on Monday, January 9th 2012 at 11:26 GMT by Market Wire
Aethlon Medical Discloses Availability of the Biotech Showcase? 2012 Presentation -- SAN DIEGO, Jan. 9, 2012 /PRNewswire/ --
Aethlon Medical Discloses Availability of the Biotech Showcase? 2012 Presentation
SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that an audio rebroadcast of the presentation by its Chairman and CEO, James A. Joyce, at the Biotech Showcase™ 2012, on January 9, 2012, is now be available at:
(Photo: [ http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ])
[ http://www.media-server.com/m/p/dfvbu2du ]
In addition, the slide presentation is available at:
[ http://aethlonmedical.investorroom.com/index.php?s=19 ]
Biotech Showcase™ provides private and public life science companies the opportunity to present to an audience of investors and business development executives during the course of the industry's largest annual healthcare investor conference.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit [ www.aethlonmedical.com ].
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
[ jj@aethlonmedical.com ]
Jim Frakes
Chief Financial Officer
858.459.7800 x300
[ jfrakes@aethlonmedical.com ]
John P. Salvador
Director, Communications
858.459.7800 x307
[ jps@aethlonmedical.com ]
SOURCE Aethlon Medical, Inc.
[ Back to top ] RELATED LINKS
[ http://www.aethlonmedical.com ]
